

Laurence H Klotz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7660489/laurence-h-klotz-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

373
papers

17,618
citations

61
h-index

126
g-index

460
ext. papers

20,964
ext. citations

4.5
avg, IF

6.94
L-index

#	Paper	IF	Citations
373	Low Serum Testosterone in Men With Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors-A Radical PC Substudy.. <i>Journal of Urology</i> , 2022 , 101097JU00000000000002384	2.5	0
372	Effect of F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial.. <i>Radiology</i> , 2022 , 211824	20.5	4
371	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.. <i>European Urology Open Science</i> , 2022 , 37-50-57	0.9	1
370	A protocol for the VISION study: An individual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultrasound guided biopsy in the detection of prostate cancer.. <i>PLoS ONE</i> , 2022 , 17, e0263345	3.7	0
369	Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.. <i>Human Genetics and Genomics Advances</i> , 2022 , 3, 100070-100070	0.8	1
368	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. <i>European Urology</i> , 2022 ,	10.2	2
367	Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. <i>Contemporary Clinical Trials</i> , 2021 , 112, 106618	2.3	3
366	When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy. <i>Canadian Urological Association Journal</i> , 2021 , 15, 115-121	1.2	3
365	Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. <i>Canadian Urological Association Journal</i> , 2021 , 15, 181-186	1.2	7
364	Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis. <i>Canadian Urological Association Journal</i> , 2021 , 15, E11-E16	1.2	21
363	Impact of COVID-19 on medical education: introducing homo digitalis. <i>World Journal of Urology</i> , 2021 , 39, 1997-2003	4	6
362	Scoping review: hotspots for COVID-19 urological research: what is being published and from where?. <i>World Journal of Urology</i> , 2021 , 39, 3151-3160	4	1
361	The 'C' Words: parallels and analogies between Prostate Cancer and Covid-19. <i>World Journal of Urology</i> , 2021 , 39, 3175-3176	4	0
360	Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. <i>Journal of Urology</i> , 2021 , 205, 769-779	2.5	11
359	Reply by Authors. <i>Journal of Urology</i> , 2021 , 205, 779	2.5	1
358	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 781.e17-781.e24	2.8	2
357	The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. <i>European Urology</i> , 2021 , 79, 446-452	10.2	10

356	Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. <i>European Urology Oncology</i> , 2021 ,	6.7	1
355	Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 534-542	13.4	31
354	Adding prostate-specific membrane antigen positron emission tomography (PSMA PET) to our prostate cancer armamentarium raises many questions. <i>Canadian Urological Association Journal</i> , 2021 , 15, 179-180	1.2	3
353	Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer. <i>Journal of Urology</i> , 2021 , 206, 1166-1176	2.5	1
352	Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? <i>Eur Urol Oncol</i> . In press: Incidental Prostate Cancer: An Example of How Important Guidelines Are, Especially When Evidence Is Limited. <i>European Urology Oncology</i> , 2021 , 5, 261-261	6.7	
351	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. <i>BJU International</i> , 2021 , 127, 96-107	5.6	3
350	Moving away from systematic biopsies: image-guided prostate biopsy (in-bore biopsy, cognitive fusion biopsy, MRUS fusion biopsy) -literature review. <i>World Journal of Urology</i> , 2021 , 39, 677-686	4	0
349	Current evidence for focal therapy and partial gland ablation for organ-confined prostate cancer: systematic review of literature published in the last 2 years. <i>Current Opinion in Urology</i> , 2021 , 31, 49-57	2.8	1
348	Age-Related Mental Health Consequences of COVID-19: A Global Perspective. <i>Sociedade Brasileira de Urologia</i> , 2021 , 47, 1-10	0.1	
347	Overdiagnosis in urologic cancer : For World Journal of Urology Symposium on active surveillance in prostate and renal cancer. <i>World Journal of Urology</i> , 2021 , 1	4	3
346	Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. <i>European Urology Focus</i> , 2021 ,	5.1	1
345	Letter - Can micro-ultrasound be the new first-choice test for patients with a suspicion of prostate cancer? RE: Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer, <i>CUAJ</i> , Jan 2021 (with author reply). <i>Canadian Urological Association Journal</i> , 2021 , 15, E127-E128	1.2	0
344	Reply by Authors. <i>Journal of Urology</i> , 2021 , 206, 1176	2.5	
343	Influence of Sociodemographic Factors on Definitive Intervention Among Low-risk Active Surveillance Patients. <i>Urology</i> , 2021 , 155, 117-123	1.6	2
342	Re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. <i>Eur Urol</i> 2021;80:442-9. <i>European Urology</i> , 2021 , 80, e100	10.2	4
341	THE CARDIOVASCULAR EFFECTS OF GNRH ANTAGONISTS IN MEN WITH PROSTATE CANCER. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	7
340	Systematic review and meta-analysis of trials evaluating the role of adjuvant radiation after radical prostatectomy for prostate cancer: Implications for early salvage. <i>Canadian Urological Association Journal</i> , 2020 , 14, 330-336	1.2	3
339	Impact of COVID-19 on Urology Practice: A Global Perspective and Snapshot Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	11

338	Prioritising Urological Surgery in the COVID-19 Era: A Global Reflection on Guidelines. <i>European Urology Focus</i> , 2020 , 6, 1104-1110	5.1	10
337	Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. <i>Nature Reviews Urology</i> , 2020 , 17, 469-481	5.5	10
336	The history of intermittent androgen deprivation therapy - A Canadian story. <i>Canadian Urological Association Journal</i> , 2020 , 14, 159-162	1.2	4
335	Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. <i>Canadian Urological Association Journal</i> , 2020 , 14, E453-E457	1.2	6
334	A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 343-350	3.3	20
333	Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database. <i>Canadian Urological Association Journal</i> , 2020 , 14, 24-30	1.2	2
332	Analysis of small non-coding RNAs in urinary exosomes to classify prostate cancer into low-grade (GG1) and higher-grade (GG2-5).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 277-277	2.2	0
331	The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 364-364	2.2	2
330	Comparison of micro-ultrasound and multiparametric MRI imaging for prostate cancer: A multicenter prospective analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 296-296	2.2	
329	Contribution of extragonadal steroids to the androgen receptor activity and to the castration-resistance development in recurrent prostate cancers after primary therapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 148-148	2.2	
328	Reply by Authors. <i>Journal of Urology</i> , 2020 , 204, 475	2.5	
327	Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 131-131	2.2	2
326	Comparative efficacy of local versus systemic salvage therapies for recurrent prostate cancer after primary radiotherapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 221-221	2.2	
325	Reply by Authors. <i>Journal of Urology</i> , 2020 , 203, 1093	2.5	
324	Active surveillance for low-risk prostate cancer - in pursuit of a standardized protocol. <i>Central European Journal of Urology</i> , 2020 , 73, 123-126	0.9	1
323	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020 , 203, 1085-1093	2.5	20
322	Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. <i>Journal of Urology</i> , 2020 , 203, 940-948	2.5	3
321	Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. <i>Journal of Urology</i> , 2020 , 204, 416-426	2.5	4

320	Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. <i>Journal of Urology</i> , 2020 , 204, 466-475	2.5	11
319	Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer. <i>Journal of Urology</i> , 2020 , 204, 934-940	2.5	4
318	Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. <i>European Urology</i> , 2020 , 77, 311-317	10.2	50
317	Active surveillance in intermediate-risk prostate cancer. <i>BJU International</i> , 2020 , 125, 346-354	5.6	23
316	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. <i>Cancer</i> , 2020 , 126, 583-592	6.4	7
315	Can high resolution micro-ultrasound replace MRI in the diagnosis of prostate cancer?. <i>European Urology Focus</i> , 2020 , 6, 419-423	5.1	13
314	Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 929.e1-929.e10	2.8	3
313	Outreach and Influence of Surgical Societies' Recommendations on Minimally Invasive Surgery During the COVID-19 Pandemic-An Anonymized International Urologic Expert Inquiry. <i>Urology</i> , 2020 , 145, 73-78	1.6	2
312	Patients' perspective of telephone visits during the COVID-19 pandemic. <i>Canadian Urological Association Journal</i> , 2020 , 14, E402-E406	1.2	3
311	Cross-continental comparison of safety and protection measures amongst urologists during COVID-19. <i>International Journal of Urology</i> , 2020 , 27, 981-989	2.3	1
310	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , 2020 , 3, 80-91	6.7	11
309	Intermediate-risk Prostate Cancer: Stratification and Management. <i>European Urology Oncology</i> , 2020 , 3, 270-280	6.7	26
308	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. <i>European Urology</i> , 2019 , 76, 693-702	10.2	12
307	Value of Increasing Biopsy Cores per Target with Cognitive MRI-targeted Transrectal US Prostate Biopsy. <i>Radiology</i> , 2019 , 291, 83-89	20.5	30
306	Contemporary approach to active surveillance for favorable risk prostate cancer. <i>Asian Journal of Urology</i> , 2019 , 6, 146-152	2.7	20
305	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 61-66	4	3
304	Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 297.e9-297.e17	2.8	15
303	Surveillance after prostate focal therapy. <i>World Journal of Urology</i> , 2019 , 37, 397-407	4	33

302	Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 24-38	6.2	108
301	Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. <i>European Urology</i> , 2019 , 75, 300-309	10.2	71
300	Discordance between testosterone measurement methods in castrated prostate cancer patients. <i>Endocrine Connections</i> , 2019 , 8, 132-140	3.5	4
299	Impact of compliance on outcomes for patients on active surveillance for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 36-36	2.2	1
298	A phase I pilot study of preoperative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 60-60	2.2	
297	Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. <i>Journal of Urology</i> , 2019 , 201, 113-119	2.5	30
296	Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. <i>Journal of Urology</i> , 2019 , 201, 721-727	2.5	9
295	Re: Prostate Cancer-specific Mortality Across Gleason Scores in Black vs Nonblack Men. <i>European Urology</i> , 2019 , 75, 1036-1037	10.2	0
294	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. <i>European Urology Oncology</i> , 2019 , 2, 333-336	6.7	4
293	Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model. <i>Anticancer Research</i> , 2019 , 39, 113-118	2.3	4
292	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. <i>European Urology</i> , 2019 , 75, 523-531	10.2	33
291	Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner. <i>Prostate</i> , 2019 , 79, 151-159	4.2	23
290	Active surveillance in intermediate risk prostate cancer. <i>Archivos Espanoles De Urologia</i> , 2019 , 72, 157-166.4	6.4	1
289	Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians. <i>Canadian Urological Association Journal</i> , 2018 , 12, E59-E63	1.2	
288	Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance. <i>Journal of Urology</i> , 2018 , 199, 1475-1481	2.5	19
287	Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 187-195	6.2	5
286	A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA 'grey zone'. <i>World Journal of Urology</i> , 2018 , 36, 341-348	4	10
285	Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. <i>Journal of Urology</i> , 2018 , 199, 990-997	2.5	183

284	Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. <i>Journal of Urology</i> , 2018 , 199, 683-690	2.5	393
283	A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence Following Radical Local Therapy. <i>Journal of Urology</i> , 2018 , 200, 335-343	2.5	6
282	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , 2018 , 378, 1767-1777	59.2	1250
281	Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. <i>Journal of Urology</i> , 2018 , 199, 147-154	2.5	26
280	Active surveillance for localized prostate cancer 2018 , 289-296		
279	Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Analysis of the PR.7 Trial. <i>Clinical Cancer Research</i> , 2018 , 24, 5305-5312	12.9	10
278	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. <i>Annals of Internal Medicine</i> , 2018 , 168, 1-9	8	25
277	Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. <i>European Urology Oncology</i> , 2018 , 1, 238-241	6.7	21
276	Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement. <i>Canadian Urological Association Journal</i> , 2018 , 12, 30-37	1.2	11
275	Surveillance at the Margins: Management of High-Volume Gleason 6, PSA > 10, or Gleason 3 + 4. <i>Current Clinical Urology</i> , 2018 , 65-69		
274	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. <i>BMC Urology</i> , 2018 , 18, 78	2.2	6
273	Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. <i>BMC Urology</i> , 2018 , 18, 77	2.2	1
272	Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2018 , 4, 1133	13.4	
271	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. <i>European Urology</i> , 2017 , 71, 648-655	10.2	132
270	The drama of prostate cancer diagnostics. <i>Lancet Oncology</i> , 2017 , 18, e132	21.7	0
269	Active surveillance for low-risk prostate cancer. <i>Current Opinion in Urology</i> , 2017 , 27, 225-230	2.8	28
268	Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. <i>Nature Reviews Urology</i> , 2017 , 14, 312-322	5.5	37
267	Contemporary Active Surveillance: Candidate Selection, Follow-up Tools, and Expected Outcomes. <i>Urologic Clinics of North America</i> , 2017 , 44, 565-574	2.9	15

266	A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol. <i>BMJ Open</i> , 2017 , 7, e017863	3	9
265	Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. <i>Canadian Urological Association Journal</i> , 2017 , 11, 16-23	1.2	12
264	Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. <i>Canadian Urological Association Journal</i> , 2017 , 11, E62-E63	1.2	
263	What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy?. <i>Canadian Urological Association Journal</i> , 2017 , 11, 118-122	1.2	2
262	Active Surveillance for Intermediate Risk Prostate Cancer. <i>Current Urology Reports</i> , 2017 , 18, 80	2.9	24
261	The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2017 , 197, 1068-1075	2.5	25
260	Appropriateness Criteria for Active Surveillance of Prostate Cancer. <i>Journal of Urology</i> , 2017 , 197, 67-74	2.5	33
259	Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. <i>European Urology</i> , 2017 , 71, 534-542	10.2	21
258	Evaluation of Focal Ablation of Magnetic Resonance Imaging Defined Prostate Cancer Using Magnetic Resonance Imaging Controlled Transurethral Ultrasound Therapy with Prostatectomy as the Reference Standard. <i>Journal of Urology</i> , 2017 , 197, 255-261	2.5	20
257	Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance. <i>Journal of Urology</i> , 2017 , 197, 335-341	2.5	30
256	Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. <i>European Urology</i> , 2017 , 71, 274-280	10.2	9
255	Active Surveillance for Low-Risk Prostate Cancer 2017 , 113-125		
254	Evaluating Metformin as a Potential Chemosensitizing Agent when Combined with Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Cells. <i>Anticancer Research</i> , 2017 , 37, 6601-6607	2.3	5
253	Active Surveillance for Low Risk Prostate Cancer 2017 , 161-170		1
252	Low-Risk Prostate Cancer in North America: Rationale, Uptake, and Limitations of Active Surveillance and Opportunities for Focal Therapy. <i>Current Clinical Urology</i> , 2017 , 51-56		
251	Active Surveillance for Prostate Cancer: How to Do It Right. <i>Oncology</i> , 2017 , 31, 333-40, 345	1.8	20
250	Intermittent Androgen Deprivation Therapy-An Important Treatment Option for Prostate Cancer. <i>JAMA Oncology</i> , 2016 , 2, 1531-1532	13.4	10
249	Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. <i>Journal of Urology</i> , 2016 , 196, 1651-1658	2.5	118

248	Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression: Con. <i>Journal of Urology</i> , 2016 , 196, 985-8	2.5	6
247	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. <i>Lancet Oncology</i> , 2016 , 17, 153-163	21.7	164
246	Active Surveillance: Rationale, Patient Selection, Follow-up, and Outcomes 2016 , 215-223		
245	Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials. <i>Therapeutic Advances in Urology</i> , 2016 , 8, 75-82	3.2	13
244	Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance. <i>Journal of Urology</i> , 2016 , 195, 1409-1414	2.5	84
243	New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men. <i>European Urology</i> , 2016 , 69, 933-41	10.2	11
242	Current Status of Clinical Trials in Active Surveillance 2016 , 141-152		
241	Efficacy and safety of enzalutamide vs bicalutamide in European and North American men participating in the TERRAIN trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5063-5063	2.2	
240	The uptake of active surveillance for the management of prostate cancer: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2016 , 10, 333-338	1.2	12
239	Surgery Provides Better Oncologic Outcomes than Radiation for the Treatment of Prostate Cancer. <i>Journal of Urology</i> , 2016 , 196, 309-11	2.5	1
238	Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort. <i>Journal of Urology</i> , 2015 , 194, 79-84	2.5	53
237	A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2015 , 464, 848-54	3.4	19
236	Active surveillance for low-risk prostate cancer. <i>Current Urology Reports</i> , 2015 , 16, 24	2.9	31
235	Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1151-6	2.2	109
234	Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. <i>World Journal of Urology</i> , 2015 , 33, 907-16	4	9
233	Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1795-802	5.5	11
232	Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 272-7	2.2	747
231	World Urologic Oncology Federation Bladder Cancer Prevention Program: a global initiative. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 25-29	2.8	24

230	Capsaicin: a novel radio-sensitizing agent for prostate cancer. <i>Prostate</i> , 2015 , 75, 113-25	4.2	28
229	A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. <i>Journal of Magnetic Resonance Imaging</i> , 2015 , 41, 220-5	5.6	75
228	Capsaicin reduces the metastatic burden in the transgenic adenocarcinoma of the mouse prostate model. <i>Prostate</i> , 2015 , 75, 1300-11	4.2	37
227	Upper limit of cancer extent on biopsy defining very low-risk prostate cancer. <i>BJU International</i> , 2015 , 116, 213-9	5.6	18
226	Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort Study. <i>Journal of Cancer</i> , 2015 , 6, 1160-71	4.5	26
225	Active surveillance for the management of localized prostate cancer: Guideline recommendations. <i>Canadian Urological Association Journal</i> , 2015 , 9, 171-8	1.2	129
224	The effects of serum from prostate cancer patients with elevated body mass index on prostate cancer cells in vitro. <i>Lipid Insights</i> , 2015 , 8, 11-9	1	14
223	Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis. <i>Urology</i> , 2015 , 85, 621-7	1.6	21
222	Survivorship and improving quality of life in men with prostate cancer. <i>European Urology</i> , 2015 , 68, 374-83	10.2	65
221	Defining 'progression' and triggers for curative intervention during active surveillance. <i>Current Opinion in Urology</i> , 2015 , 25, 258-66	2.8	14
220	Testosterone therapy and prostate cancer--safety concerns are well founded. <i>Nature Reviews Urology</i> , 2015 , 12, 48-54	5.5	19
219	Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. <i>European Urology</i> , 2015 , 67, 627-36	10.2	234
218	Active surveillance and focal therapy for low-intermediate risk prostate cancer. <i>Translational Andrology and Urology</i> , 2015 , 4, 342-54	2.3	15
217	Reply by the authors. <i>Urology</i> , 2014 , 84, 1250-1	1.6	
216	Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise. <i>BJU International</i> , 2014 , 113, E82-9	5.6	8
215	Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. <i>European Urology</i> , 2014 , 66, 619-22	10.2	43
214	Maximal testosterone suppression in prostate cancer--free vs total testosterone. <i>Urology</i> , 2014 , 83, 1217-22	10.2	16
213	Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. <i>European Urology</i> , 2014 , 66, 1101-8	10.2	71

212	Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. <i>Urology</i> , 2014 , 83, 1122-8	1.6	41
211	Management of low risk prostate cancer-active surveillance and focal therapy. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 324-34	19.4	50
210	Practice patterns of post-radical prostatectomy incontinence surgery in Ontario. <i>Canadian Urological Association Journal</i> , 2014 , 8, E670-4	1.2	3
209	Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial. <i>Canadian Urological Association Journal</i> , 2014 , 8, E789-94	1.2	8
208	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 465, 623-8	5.1	33
207	The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, American Society of Cytopathology, and the European Association of Urology	5	99
206	GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1126-34	2.8	44
205	Active surveillance for clinically localized prostate cancer--a systematic review. <i>Journal of Surgical Oncology</i> , 2014 , 109, 830-5	2.8	107
204	Management of low risk prostate cancer: active surveillance and focal therapy. <i>Current Opinion in Urology</i> , 2014 , 24, 270-9	2.8	21
203	Conservative management for low-risk prostate cancer improves quality-adjusted life expectancy at lower cost compared with initial treatment. <i>Evidence-Based Medicine</i> , 2014 , 19, 40		
202	Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. <i>European Urology</i> , 2014 , 65, 565-73	10.2	191
201	Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. <i>Lancet Oncology, The</i> , 2014 , 15, 223-31	21.7	155
200	Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other. <i>Oncology</i> , 2014 , 28, 950-C3	1.8	7
199	Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer. <i>Current Urology Reports</i> , 2013 , 14, 159-67	2.9	13
198	Exercise does not counteract the effects of a "westernized" diet on prostate cancer xenografts. <i>Prostate</i> , 2013 , 73, 1223-32	4.2	6
197	Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. <i>European Urology</i> , 2013 , 63, 125-40	10.2	425
196	A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. <i>European Urology</i> , 2013 , 63, 927-35	10.2	58
195	Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. <i>European Urology</i> , 2013 , 64, 544-52	10.2	309

194	Prostate cancer screening: Canadian guidelines 2011. <i>Canadian Urological Association Journal</i> , 2013 , 5, 235	1.2	
193	Active surveillance for low-risk prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 85, 295-302		39
192	Active surveillance for prostate cancer: overview and update. <i>Current Treatment Options in Oncology</i> , 2013 , 14, 97-108	5.4	53
191	Prostate cancer overdiagnosis and overtreatment. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013 , 20, 204-9	4	91
190	Active surveillance: patient selection. <i>Current Opinion in Urology</i> , 2013 , 23, 239-44	2.8	34
189	Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer. <i>Canadian Urological Association Journal</i> , 2013 , 7, 450-3	1.2	4
188	Still unconvinced on the use of salvage prostatectomy. <i>Canadian Urological Association Journal</i> , 2013 , 7, 93	1.2	
187	MR thermometry in the human prostate gland at 3.0T for transurethral ultrasound therapy. <i>Journal of Magnetic Resonance Imaging</i> , 2013 , 38, 1564-71	5.6	23
186	Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 1498-507	5.6	70
185	Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1050-8	9.7	164
184	Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1-1	2.2	1
183	Comparision of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 42-42	2.2	2
182	Active Surveillance for Favorable-Risk Prostate Cancer 2013 , 621-629		
181	Active surveillance not only reduces morbidity, It saves lives. <i>Oncology</i> , 2013 , 27, 522, 593	1.8	0
180	Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. <i>European Urology</i> , 2012 , 61, 961-71	10.2	180
179	Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer. <i>European Urology</i> , 2012 , 61, 851-4	10.2	9
178	Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort. <i>BJU International</i> , 2012 , 110, 195-200	5.6	14
177	How (not) to communicate new scientific information: a memoir of the famous Brindley lecture. <i>Trends in Urology & Men's Health</i> , 2012 , 3, 35-36	0.3	

176	Active surveillance for prostate cancer: a systematic review of the literature. <i>European Urology</i> , 2012 , 62, 976-83	10.2	434
175	Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. <i>Journal of Urology</i> , 2012 , 187, 1247-52	2.5	140
174	Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes. <i>Current Urology Reports</i> , 2012 , 13, 153-9	2.9	25
173	Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. <i>BJU International</i> , 2012 , 109 Suppl 2, 1-7	5.6	14
172	Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. <i>International Journal of Urology</i> , 2012 , 19, 594-601	2.3	61
171	Active surveillance: the Canadian experience with an "inclusive approach". <i>Journal of the National Cancer Institute Monographs</i> , 2012 , 2012, 234-41	4.8	18
170	Active surveillance: the Canadian experience. <i>Current Opinion in Urology</i> , 2012 , 22, 222-30	2.8	21
169	Intermittent androgen suppression for rising PSA level after radiotherapy. <i>New England Journal of Medicine</i> , 2012 , 367, 895-903	59.2	335
168	Canadian Consensus Conference: The FDA decision on the use of 5ARIs. <i>Canadian Urological Association Journal</i> , 2012 , 6, 83-8	1.2	5
167	Cancer overdiagnosis and overtreatment. <i>Current Opinion in Urology</i> , 2012 , 22, 203-9	2.8	49
166	Active surveillance for low-risk prostate cancer. <i>F1000 Medicine Reports</i> , 2012 , 4, 16		9
165	Active Surveillance: The Canadian Experience 2012 , 95-105		2
164	Active Surveillance Comes of Age 2012 , 215-223		
163	Active Surveillance for Favorable Risk Prostate Cancer: Background, Patient Selection, Triggers for Intervention, and Outcomes 2012 , 85-91		
162	Role of 5-alpha-reductase inhibitors in active surveillance of patients with low-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 14-14	2.2	
161	Tout est dans l'emplacement : des biopsies prostatiques et de l'IRM. <i>Canadian Urological Association Journal</i> , 2012 , 6, 81-81	1.2	78
160	High-dose oral vitamin D3 administration increases serum and prostate levels of vitamin D metabolites safely in prostate cancer patients. <i>FASEB Journal</i> , 2012 , 26, 388.5	0.9	
159	Statin Clinical Trial (REALITY) for prostate cancer: an over 15-year wait is finally over thanks to a dietary supplement. <i>Urologic Clinics of North America</i> , 2011 , 38, 325-31	2.9	12

158	Feasibility and safety of silicone rubber contrast-enhanced microcomputed tomography in evaluating the angioarchitecture of prostatectomy specimens. <i>Translational Oncology</i> , 2011 , 4, 173-7	4.9	2
157	Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. <i>Journal of Urology</i> , 2011 , 186, 1835-42	2.5	45
156	Age-related properties of the tumour vasculature in renal cell carcinoma. <i>BJU International</i> , 2011 , 107, 416-24	5.6	19
155	Prostate cancer immunology - an update for Urologists. <i>BJU International</i> , 2011 , 107, 1046-51	5.6	17
154	A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. <i>European Urology</i> , 2011 , 59, 543-52	10.2	689
153	Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. <i>European Urology</i> , 2011 , 59, 863-7	10.2	123
152	1293 PREVIOUSLY DEVELOPED SYSTEMS-BASED BIOPSY MODEL (PROSTATE PX+) IDENTIFIES FAVORABLE-RISK PROSTATE CANCER FOR MEN ENROLLED IN AN ACTIVE SURVEILLANCE PROGRAM. <i>Journal of Urology</i> , 2011 , 185,	2.5	4
151	Early prostate cancer--treat or watch?. <i>New England Journal of Medicine</i> , 2011 , 365, 569	59.2	14
150	Active surveillance for low-risk prostate cancer: an update. <i>Nature Reviews Urology</i> , 2011 , 8, 312-20	5.5	55
149	Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 1549-56	27.4	1150
148	Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2959-64	2.2	67
147	The decline and fall of RCTs. <i>Canadian Urological Association Journal</i> , 2011 , 5, 229	1.2	1
146	Prostate cancer screening: Canadian guidelines 2011. <i>Canadian Urological Association Journal</i> , 2011 , 5, 235-40	1.2	42
145	Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3443-9	2.2	174
144	New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. <i>Cancer Biology and Therapy</i> , 2011 , 12, 997-1004	4.6	31
143	Active surveillance for prostate cancer: progress and promise. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3669-76	2.2	223
142	USPSTF and FDA: PSA and 5ARIs. <i>Canadian Urological Association Journal</i> , 2011 , 5, 373-4	1.2	1
141	Le déclin et la chute des ECR. <i>Canadian Urological Association Journal</i> , 2011 , 5, 231	1.2	

140	L'USPSTF et la FDA: l'APS et les ISAR. <i>Canadian Urological Association Journal</i> , 2011 , 5, 375-6	1.2	
139	Active surveillance for prostate cancer: a review. <i>Archivos Espanoles De Urologia</i> , 2011 , 64, 806-14	0.4	9
138	EBM in Canadian urology. <i>Canadian Urological Association Journal</i> , 2010 , 4, 83-4	1.2	
137	Improving quality of care. <i>Canadian Urological Association Journal</i> , 2010 , 4, 299-301	1.2	4
136	Active surveillance for favorable-risk prostate cancer: a short review. <i>Korean Journal of Urology</i> , 2010 , 51, 665-70		12
135	Reply to F. Campodonico et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e212-e212	2.2	
134	Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 126-31	2.2	863
133	Reply to P.B. Singh et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e514-e514	2.2	1
132	Active surveillance for prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 2411-2	27.4	27
131	Reply to J.B. Aragon-Ching. <i>Journal of Clinical Oncology</i> , 2010 , 28, e267-e267	2.2	
130	Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. <i>Journal of Urology</i> , 2010 , 184, 1942-6	2.5	46
129	Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. <i>Journal of Urology</i> , 2010 , 184, 131-5	2.5	68
128	Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. <i>Journal of Urology</i> , 2010 , 183, 963-8	2.5	319
127	Antiproliferative mechanisms of the flavonoids 2,2'-dihydroxychalcone and fisetin in human prostate cancer cells. <i>Nutrition and Cancer</i> , 2010 , 62, 668-81	2.8	29
126	Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 397, 537-42	3.4	35
125	MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies. <i>Urology</i> , 2010 , 76, 1506-11	1.6	66
124	Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. <i>Journal of Urology</i> , 2010 , 184, 2313-9	2.5	56
123	Dietary Agents for Prostate Cancer Chemoprevention: An Overview. <i>Current Cancer Therapy Reviews</i> , 2010 , 6, 308-316	0.4	2

122	Active surveillance for prostate cancer: a review. <i>Current Urology Reports</i> , 2010 , 11, 165-71	2.9	66
121	Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole G, Bostwick D, Brawley O, et al. <i>N Engl J Med</i> 2010;362:1192-202. <i>European Urology</i> , 2010 , 58, 313	10.2	2
120	What can surrogate tissues tell us about the oxidative stress status of the prostate? A hypothesis-generating in-vivo study. <i>PLoS ONE</i> , 2010 , 5, e15880	3.7	5
119	The case for prostate capsule-sparing radical cystectomy in selected patients. <i>Canadian Urological Association Journal</i> , 2009 , 3, S215-9	1.2	3
118	Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists. <i>Canadian Urological Association Journal</i> , 2009 , 3, 460-4	1.2	3
117	. <i>Canadian Urological Association Journal</i> , 2009 , 3, 187-188	1.2	2
116	[Not Available]. <i>Canadian Urological Association Journal</i> , 2009 , 3, 185-6	1.2	
115	The importance of feedback. <i>Canadian Urological Association Journal</i> , 2009 , 3, 9-10	1.2	
114	The editor is back. <i>Canadian Urological Association Journal</i> , 2009 , 3, 277-278	1.2	
113	A combination of micronutrients is beneficial in reducing the incidence of prostate cancer and increasing survival in the Lady transgenic model. <i>Cancer Prevention Research</i> , 2009 , 2, 473-83	3.2	36
112	Emerging drugs for prostate cancer. <i>Expert Opinion on Emerging Drugs</i> , 2009 , 14, 455-70	3.7	5
111	Utility of incorporating genetic variants for the early detection of prostate cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 1787-93	12.9	47
110	Prostate capsule sparing radical cystectomy: oncologic safety and clinical outcome. <i>Therapeutic Advances in Urology</i> , 2009 , 1, 43-50	3.2	5
109	The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 81-6	2.8	25
108	Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback. <i>Physics in Medicine and Biology</i> , 2009 , 54, 2615-33	3.8	56
107	Active surveillance for favorable risk prostate cancer. <i>Pro. Journal of Urology</i> , 2009 , 182, 2565-6	2.5	1
106	Gleason grading controversies: what the chemoprevention trials have taught us. <i>Canadian Urological Association Journal</i> , 2009 , 3, S115-20	1.2	1
105	Degarelix acetate for the treatment of prostate cancer. <i>Drugs of Today</i> , 2009 , 45, 725-30	2.5	2

104	The impact of surgical complexities. <i>Canadian Urological Association Journal</i> , 2008 , 2, 9	1.2	
103	The bright future of the CUA. <i>Canadian Urological Association Journal</i> , 2008 , 2, 365-6	1.2	
102	Meeting your high expectations. <i>Canadian Urological Association Journal</i> , 2008 , 2, 595-6	1.2	
101	Index!!!. <i>Canadian Urological Association Journal</i> , 2008 , 2, 91	1.2	
100	Indexation: not quite yet. <i>Canadian Urological Association Journal</i> , 2008 , 2, 169-71	1.2	
99	The improved CUA Office of Education. <i>Canadian Urological Association Journal</i> , 2008 , 2, 491-3	1.2	
98	The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. <i>BJU International</i> , 2008 , 102, 1531-8	5.6	402
97	Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2008 , 6, 46-52	3.3	42
96	Re: cumulative association of five genetic variants with prostate cancer. <i>European Urology</i> , 2008 , 53, 1298-9	10.2	0
95	Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?. <i>Seminars in Radiation Oncology</i> , 2008 , 18, 2-6	5.5	21
94	Maximal androgen blockade for advanced prostate cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008 , 22, 331-40	6.5	35
93	What is the best approach for screen-detected low volume cancers?--The case for observation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 495-9	2.8	9
92	A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. <i>Radiotherapy and Oncology</i> , 2008 , 88, 53-60	5.3	24
91	Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention. <i>Nature Reviews Urology</i> , 2008 , 5, 2-3		19
90	Nomogram for predicting survival in men with clinically localized prostate cancer who do not undergo definitive therapy. <i>Nature Reviews Urology</i> , 2008 , 5, 362-3		4
89	Active surveillance for prostate cancer: trials and tribulations. <i>World Journal of Urology</i> , 2008 , 26, 437-424		52
88	The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate. <i>Prostate</i> , 2008 , 68, 345-53	4.2	10
87	L'effet des complexit� chirurgicales. <i>Canadian Urological Association Journal</i> , 2008 , 2, 11	1.2	

86	Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists. <i>Canadian Urological Association Journal</i> , 2007 , 1, S69-70	1.2	1
85	The uses of error. <i>Canadian Urological Association Journal</i> , 2007 , 1, 235	1.2	
84	Health advocacy in urology training. <i>Canadian Urological Association Journal</i> , 2007 , 1, 356	1.2	
83	Un plaidoyer pour la sant� dans la formation en urologie. <i>Canadian Urological Association Journal</i> , 2007 , 1, 357	1.2	
82	A new journal and new opportunities. <i>Canadian Urological Association Journal</i> , 2007 , 1, 9	1.2	
81	Un nouveau journal et de nouvelles possibilit�. <i>Canadian Urological Association Journal</i> , 2007 , 1, 11	1.2	
80	Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. <i>Cancer</i> , 2007 , 109, 858-67	6.4	58
79	A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. <i>European Urology</i> , 2007 , 51, 1606-15	10.2	275
78	Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?. <i>Current Urology Reports</i> , 2007 , 8, 341-4	2.9	1
77	Active surveillance for favorable-risk prostate cancer: who, how and why?. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 692-8		25
76	Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1793-800	9.7	145
75	Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. <i>Cancer Biology and Therapy</i> , 2007 , 6, 40-5	4.6	133
74	Outcomes of treatment vs observation of localized prostate cancer in elderly men. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1651-2; author reply 1652-3	27.4	
73	Point: active surveillance for favorable risk prostate cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 693-8	7.3	2
72	Urothelial carcinoma of the prostate. <i>Urology</i> , 2007 , 69, 50-61	1.6	54
71	Results of unilateral genitofemoral nerve grafts with contralateral nerve sparing during radical prostatectomy. <i>Urology</i> , 2007 , 69, 1161-4	1.6	11
70	Active surveillance for favorable risk prostate cancer: rationale, risks, and results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 505-9	2.8	24
69	The Continuing Role of PSA in the Detection and Management of Prostate Cancer. <i>European Urology Supplements</i> , 2007 , 6, 327-333	0.9	5

68	Localised and Locally Advanced Prostate Cancer: Who to Treat and How?. <i>European Urology Supplements</i> , 2007 , 6, 334-343	0.9	3
67	Advanced Prostate Cancer: Hormones and Beyond. <i>European Urology Supplements</i> , 2007 , 6, 354-364	0.9	3
66	PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice. <i>Canadian Urological Association Journal</i> , 2007 , 1, 17-21	1.2	9
65	Active surveillance versus radical treatment for favorable-risk localized prostate cancer. <i>Current Treatment Options in Oncology</i> , 2006 , 7, 355-62	5.4	55
64	Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. <i>Cancer</i> , 2006 , 107, 389-95	6.4	78
63	Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. <i>Clinical Cancer Research</i> , 2006 , 12, 6452-8	12.9	35
62	Combined androgen blockade: an update. <i>Urologic Clinics of North America</i> , 2006 , 33, 161-6, v-vi	2.9	15
61	Current Role of PSA Kinetics in the Management of Patients with Prostate Cancer. <i>European Urology Supplements</i> , 2006 , 5, 472-478	0.9	5
60	Active Surveillance with Selective Delayed Intervention for Favourable Risk Prostate Cancer: Clinical Experience and a Number Needed to Treat Analysis. <i>European Urology Supplements</i> , 2006 , 5, 479-486	0.9	11
59	Modeling prostate specific antigen kinetics in patients on active surveillance. <i>Journal of Urology</i> , 2006 , 176, 1392-7; discussion 1397-8	2.5	54
58	Cardiovascular effects of androgen depletion and replacement therapy. <i>Urology</i> , 2006 , 67, 1126-32	1.6	5
57	Active surveillance with selective delayed intervention for favorable risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006 , 24, 46-50	2.8	97
56	Current role of prostate-specific antigen kinetics in managing patients with prostate cancer. <i>BJU International</i> , 2006 , 97, 451-5	5.6	9
55	Androgen replacement and/or 5 alpha reductase inhibitors in aging men. <i>Canadian Journal of Urology</i> , 2006 , 13 Suppl 1, 44-5	0.8	
54	Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis. <i>Canadian Journal of Urology</i> , 2006 , 13 Suppl 1, 48-55	0.8	14
53	PSA recurrence: definitions, PSA kinetics, and identifying patients at risk. <i>Canadian Journal of Urology</i> , 2006 , 13 Suppl 2, 43-7	0.8	5
52	Combined androgen blockade: the case for bicalutamide. <i>Clinical Prostate Cancer</i> , 2005 , 3, 215-9		24
51	How (not) to communicate new scientific information: a memoir of the famous Brindley lecture. <i>BJU International</i> , 2005 , 96, 956-7	5.6	8

50	Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. <i>European Urology</i> , 2005 , 47, 16-21	10.2	62
49	Active surveillance for prostate cancer: for whom?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8165-9	2.2	269
48	The use of genetic markers to determine risk for prostate cancer at prostate biopsy. <i>Clinical Cancer Research</i> , 2005 , 11, 8391-7	12.9	46
47	Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. <i>Nature Reviews Urology</i> , 2005 , 2, 136-42; quiz 1 p following 149		34
46	Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease. <i>Canadian Journal of Urology</i> , 2005 , 12 Suppl 1, 53-7; discussion 101-2	0.8	5
45	International regional working groups on prostate cancer: results of consensus development. <i>Canadian Journal of Urology</i> , 2005 , 12 Suppl 1, 86-91	0.8	1
44	Active surveillance for good risk prostate cancer: rationale, method, and results. <i>Canadian Journal of Urology</i> , 2005 , 12 Suppl 2, 21-4	0.8	8
43	Antioxidants block prostate cancer in lady transgenic mice. <i>Cancer Research</i> , 2004 , 64, 5891-6	10.1	100
42	Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. <i>BJU International</i> , 2004 , 94, 295-8	5.6	25
41	Variation in patterns of practice in diagnosing screen-detected prostate cancer. <i>BJU International</i> , 2004 , 94, 1239-44	5.6	13
40	Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. <i>Journal of Urology</i> , 2004 , 172, S48-50; discussion S50-1	2.5	72
39	A systematic review of randomized trials in localized prostate cancer. <i>Canadian Journal of Urology</i> , 2004 , 11, 2110-7	0.8	22
38	Practice patterns of Canadian urologists in the management of stage I testicular seminoma. <i>Canadian Journal of Urology</i> , 2004 , 11, 2194-9	0.8	5
37	Restoring sexual function in prostate cancer patients: an innovative approach. <i>Canadian Journal of Urology</i> , 2004 , 11, 2285-9	0.8	10
36	Conservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?. <i>Seminars in Oncology</i> , 2003 , 30, 587-95	5.5	4
35	Active surveillance with selective delayed intervention: a biologically nuanced approach to favorable-risk prostate cancer. <i>Clinical Prostate Cancer</i> , 2003 , 2, 106-10		8
34	Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. <i>Clinical Biochemistry</i> , 2002 , 35, 471-5	3.5	21
33	Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumors. <i>Urology</i> , 2002 , 59, 551-4	1.6	14

32	Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. <i>Urology</i> , 2002 , 60, 93-7	1.6	98
31	Critical evaluation of hormonal therapy for carcinoma of the prostate. <i>Urology</i> , 2002 , 60, 201-8	1.6	75
30	Reactions. <i>Lancet, The</i> , 2002 , 360, 1869	40	
29	Expectant management with selective delayed intervention for favorable risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2002 , 7, 175-9	2.8	16
28	Feasibility Study: Watchful Waiting For Localized Low To Intermediate Grade Prostate Carcinoma With Selective Delayed Intervention Based On Prostate Specific Antigen, Histological And/Or Clinical Progression. <i>Journal of Urology</i> , 2002 , 167, 1664-1669	2.5	257
27	Modulation of Cell Proliferation and Cell Cycle Regulators by Vitamin E in Human Prostate Carcinoma Cell Lines. <i>Journal of Urology</i> , 2002 , 168, 1578-1582	2.5	80
26	Outcomes of 200 Patients with Localized Prostate Cancer Enrolled in a Watchful Waiting Protocol. <i>UroOncology</i> , 2002 , 2, 93-94		
25	Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. <i>Journal of Urology</i> , 2002 , 167, 1664-9	2.5	67
24	Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. <i>Cancer Research</i> , 2002 , 62, 2540-5	10.1	54
23	Back to nephrectomy for patients with metastatic renal cancer. <i>Lancet, The</i> , 2001 , 358, 948-9	40	5
22	Intraoperative cavernous nerve stimulation during nerve sparing radical prostatectomy: how and when?. <i>Current Opinion in Urology</i> , 2000 , 10, 239-43	2.8	26
21	Early postsurgery experience of prostate cancer patients and spouses. <i>Cancer Practice</i> , 2000 , 8, 165-71		42
20	RE: EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER. <i>Journal of Urology</i> , 2000 , 164, 1666-1666	2.5	5
19	Presurgery experiences of prostate cancer patients and their spouses. <i>Cancer Practice</i> , 1999 , 7, 130-5		117
18	CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. <i>Urology</i> , 1999 , 53, 757-63	1.6	60
17	Advances in nerve sparing for radical prostatectomy. <i>Urology</i> , 1999 , 54, 956-9	1.6	10
16	A PHASE 1-2 TRIAL OF DIETHYLSTILBESTROL PLUS LOW DOSE WARFARIN IN ADVANCED PROSTATE CARCINOMA. <i>Journal of Urology</i> , 1999 , 161, 169-172	2.5	44
15	Diet, androgens, oxidative stress and prostate cancer susceptibility. <i>Cancer and Metastasis Reviews</i> , 1998 , 17, 325-30	9.6	78

14	PREDICTORS OF PATHOLOGICAL STAGE BEFORE NEOADJUVANT ANDROGEN WITHDRAWAL THERAPY AND RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 1998 , 159, 925-928	2.5	11
13	Early experience with intraoperative cavernous nerve stimulation with penile tumescence monitoring to improve nerve sparing during radical prostatectomy. <i>Urology</i> , 1998 , 52, 537-42	1.6	69
12	Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. <i>New England Journal of Medicine</i> , 1998 , 338, 1265-71	59.2	245
11	Bacille Calmette-Guerin (BCG) associated epididymitis: a case report and review. <i>Canadian Journal of Urology</i> , 1998 , 5, 477-481	0.8	
10	Post transurethral resection of prostate incontinence in previously radiated prostate cancer patients. <i>Canadian Journal of Urology</i> , 1998 , 5, 560-563	0.8	7
9	PSAdynia and other PSA-related syndromes: a new epidemic--a case history and taxonomy. <i>Urology</i> , 1997 , 50, 831-2	1.6	35
8	Can radiotherapy salvage isolated local recurrence following radical prostatectomy?. <i>Canadian Journal of Urology</i> , 1997 , 4, 395-399	0.8	
7	Results of a survey of Canadian men with prostate cancer. <i>Canadian Journal of Urology</i> , 1997 , 4, 359-365	0.8	16
6	A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. <i>Urology</i> , 1996 , 47, 335-42	1.6	53
5	Survey of consecutive prostate cancer patients attending the Toronto Sunnybrook Regional Cancer Centre (TSRCC). <i>Canadian Journal of Urology</i> , 1996 , 3, 268-276	0.8	
4	Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence. <i>Canadian Journal of Urology</i> , 1996 , 3, 246-250	0.8	11
3	Laparoscopic retroperitoneal lymphadenectomy for high-risk stage 1 nonseminomatous germ cell tumor: report of four cases. <i>Urology</i> , 1994 , 43, 752-6	1.6	25
2	Spontaneous rupture of renal cell carcinoma associated with acute pancreatitis. <i>Urology</i> , 1993 , 42, 445-6	1.6	2
1	Intermittent endocrine therapy for advanced prostate cancer. <i>Cancer</i> , 1986 , 58, 2546-50	6.4	193